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Abstract: Non-alcoholic fatty liver disease (NAFLD) is the hepatic consequence of metabolic
syndrome, which often also includes obesity, diabetes, and dyslipidemia. The connection between
gut microbiota (GM) and NAFLD has attracted significant attention in recent years. Data has shown
that GM affects hepatic lipid metabolism and influences the balance between pro/anti-inflammatory
effectors in the liver. Although studies reveal the association between GM dysbiosis and NAFLD,
decoding the mechanisms of gut dysbiosis resulting in NAFLD remains challenging. The potential
pathophysiology that links GM dysbiosis to NAFLD can be summarized as: (1) disrupting the balance
between energy harvest and expenditure, (2) promoting hepatic inflammation (impairing intestinal
integrity, facilitating endotoxemia, and initiating inflammatory cascades with cytokines releasing),
and (3) altered biochemistry metabolism and GM-related metabolites (i.e., bile acid, short-chain
fatty acids, aromatic amino acid derivatives, branched-chain amino acids, choline, ethanol). Due
to the hypothesis that probiotics/synbiotics could normalize GM and reverse dysbiosis, there have
been efforts to investigate the therapeutic effect of probiotics/synbiotics in patients with NAFLD.
Recent randomized clinical trials suggest that probiotics/synbiotics could improve transaminases,
hepatic steatosis, and reduce hepatic inflammation. Despite these promising results, future studies are
necessary to understand the full role GM plays in NAFLD development and progression. Additionally,
further data is needed to unravel probiotics/synbiotics efficacy, safety, and sustainability as a novel
pharmacologic approaches to NAFLD.
Keywords: Non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; probiotics; microbiome
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined by an excessive accumulation of fat in the
liver tissue, when other causes of secondary hepatic fat accumulation disorders, including significant
alcohol consumption, hereditary disorders, and steatogenic medication, have been ruled out [1].
NAFLD is characterized by a large spectrum of liver disease, from isolated steatosis to steatohepatitis,
and can progress to cause hepatic fibrosis formation and cirrhosis. Among the NAFLD spectrum,
nonalcoholic steatohepatitis (NASH) is the more severe form and presents with hepatic steatosis,
lobular inflammation, and cell injury (i.e., hepatocyte ballooning) on histology [1]. NAFLD has been
recognized as one of the leading causes of chronic liver disease in the world, and its prevalence, along
with a global epidemic of metabolic syndrome, obesity, and insulin resistance, has risen sharply across
continents [2]. A recent systemic review conducted by Younossi et al. estimated that the prevalence of
NAFLD has reached 25% globally [3]. Patients with NASH are at risk of progressing to cirrhosis of the
liver and/or developing hepatocellular carcinoma (HCC). The 5-year cumulative incidence of HCC,
in the context of NASH fibrosis/cirrhosis, varies from 4% to 12.3% [4–7], and from 2002 to 2017 the
proportion of NASH-related HCC increased 8.5-fold, rising from 2.1% to 17.9% [8].
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Despite the rising prevalence of NAFLD, no definitive pharmacological treatment has been
approved by the Food and Drug Administration or the European Medicines Agency. Lifestyle changes
include physical activity, weight loss, and diet modification are currently the main strategies to mitigate
the NAFLD epidemic. Therefore, it remains essential, though challenging, to identify new therapeutic
strategies for NAFLD.
It is widely accepted that the onset and progression of NAFLD are linked to inflammation,
oxidative stress, insulin resistance, dyslipidemia, and obesity [9,10]. This process is driven by the
interaction of environmental, diet, and genetic factors via biochemical and immunological alterations
in lipid and glucose metabolism [11]. Despite decades of research on the pathogenesis of NAFLD,
the pathophysiology remains unclear and most likely with multiple mechanisms. One potential
mechanism is the direct connection via the portal vein between the intestines and liver (gut-gut
microbiota-liver axis). It is through this process that microbiota colonized in the intestine can
modulate metabolic processes that directly or indirectly impact metabolic syndrome and its associated
co-morbidities [12].
The gut microbiota (GM) has been estimated to have more than 1000 bacterial species and 100
trillion bacteria with 150-fold more genes than the human genome that colonizes in the human
intestinal tract [13,14]. The two major phyla in the human intestine are Firmicutes (Lactobacillus,
Peptoniphilus, Ruminococcus, Clostridium, and Eubacteria) and Bacteroidetes (Bacteroides, Prevotella). Other
less abundant phyla include Actinobacteria (Bifidobacterium), Proteobacteria, and Verrumicrobia [15].
However, the composition and abundance of GM varies due to considerable heterogeneity between
individuals and underlying conditions such as age, gender, diet, pregnancy, hormonal changes,
travel, infection, and medication such as antibiotics and proton pump inhibitors [16–19]. Dysbiosis
is defined as an imbalance between healthy and disease-promoting microorganisms; itis manifested
through changes of diversity and fluctuation in the relative abundance of certain microorganisms [20].
The balance and homeostasis of GM is critical for maintaining health and protecting against diseases
in the host.
There are a growing number of studies revealing the association between GM dysbiosis and
metabolic syndrome, obesity, type 2 diabetes, NAFLD [21–24]. Zhu et al. utilized 16S ribosomal RNA
sequencing and concluded that NASH patients have a distinct composition and ratio of Firmicutes,
Bacteroidetes, and Actinobacteria at the level of phylum, family, and genus compared with the healthy
group. NASH patients also had an increased abundance of alcohol-producing bacteria which could
increase serum alcohol levels and oxidative stress, resulting in liver injury [23]. Gut microbiome changes
have also been found among pediatric NAFLD subjects. Del Chierico et al. compared NAFLD, NASH,
and obese pediatric patients with healthy controls and found that NAFLD patients had an increased
abundance of Anaerococcus (Actinobacteria), Ruminococcus (Firmicutes), Peptoniphilus (Firmicutes), Dorea
(Firmicutes), Bradyrhizobium (Proteobacteria), and Propionibacterium acnes (Actinobacteria) but a reduced
abundance of Rikenellaceae (Bacteroidetes) and Oscillospira (Firmicutes). There are no significant differences
in terms of microbiome composition among the NAFLD, NASH, and obese groups [25]. Furthermore,
Boursier et al. identified that GM can be used as predictors for NAFLD severity and progression.
The abundance of Bacteroides was higher in both NASH and fibrosis patients, and Ruminococcus
abundance was higher in fibrosis patients. Through multivariate analysis Boursier et al. concluded
that Bacteroides is independently associated with NASH and Ruminococcus is linked to fibrosis [26].
Despite these studies revealing an association between GM dysbiosis and NAFLD, whether gut
dysbiosis is a causative factor that results in NAFLD remains unclear. Thus, further clarification is
necessary to investigate the causative relationship and potential pathogenesis links between NAFLD
and dysbiosis.
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2. Pathogenesis: The Links between NAFLD and Microbiome
The pathophysiology of NAFLD/NASH progression is complicated, and the “multiple hit”
hypothesis formulates the idea that multiple insults work together to facilitate the progression of
disease. Some of these insults include insulin resistance, genetic and epigenetic factors, nutritional
supplement, and gut microbiota [27]. Among the numerous pathophysiology mechanisms that result
in NAFLD/NASH, the GM has been considered to be one of the vital contributors and has received
increasing attention in recent years [28]. The liver receives portal vein circulation and is exposed
to nutritional supply as well as GM derived metabolites from the gut system. The gut-liver axis
characterized by a functional, bidirectional interaction between the gastrointestinal tract and liver
owing to the close anatomy. The GM and liver have very complicated interactive relationships and
mediated by a complex metabolic and immunologic network [29]. The primary mechanism can
be summarized as changing energy harvest mode, inflammatory cytokines and related signaling
pathways, altered biochemistry metabolism and GM-related metabolites (bile acid, short-chain fatty
acids, aromatic amino acid derivatives, branched-chain amino acids, and ethanol; see Figure 1).
Nutrients 2019, 11, x FOR PEER REVIEW 3 of 24 
supplement, and gut microbiota [27]. Among the numerous pathophysiology mechanisms that result 
in NAFLD/NASH, the GM has been considered to be one of the vital contributors and has received 
increasing attention in recent years [28]. The liver receives portal vein circulation and is exposed to 
nutritional supply as well as GM derived metabolites from the gut system. The gut-liver axis 
characterized by a functional, bidirectional interaction between the gastrointestinal tract and liver 
owing to the close anatomy. The GM and liver have very complicated interactive relationships and 
mediated by a complex metabolic and immunologic network [29]. The primary mechanism can be 
summarized as changing energy harvest mode, inflammatory cytokines and related signaling 
pathways, altered biochemistry metabolism and GM-related metabolites (bile acid, short-chain fatty 
acids, aromatic amino acid derivatives, branched-chain amino acids, and ethanol; see Figure 1).  
 
Figure 1. The roles gut microbiota play in liver steatosis. LPS: lipopolysaccharide; SCFAs: short-chain 
fatty acids; AAA: aromatic amino acids; BCAA: branched-chain amino acids; EtOH: ethanol; FXR: 
farnesoid X receptor; TGR5: transmembrane G protein-coupled receptor 5; GPR: G protein-coupled 
receptor; TMAO: trimethylamine-N-oxide; VLDL-C: very-low-density lipoprotein cholesterol; ROS: 
Reactive oxygen species; TNF-α: tumor necrosis factor-alfa; IFN- γ: Interferon-gamma; IL-1β: 
interleukin 1beta; IL-6: interleukin 6; IL-8: interleukin 8; TLR: toll-like receptor; NAFLD: Non-
alcoholic fatty liver disease. 
2.1. Interplay with Intestinal Microbiota and the Host Immune System 
Many factors such as obesity, diet, alcohol intake infection, and medication, can affect the 
microbiome and result in impaired intestinal integrity, intestinal bacterial overgrowth, bacterial 
translocation, and lipopolysaccharide (LPS) releasing. The subsequent endotoxemia enters the liver 
through the portal circulation which induces inflammatory cytokines releasing, resulting in liver 
injury that may contribute to NAFLD [30]. Miele et al. indicated that NAFLD patients have a reduced 
expression of ZO-1 (zona occludens 1), a major tight junction protein, which results in higher 
intestinal permeability [31]. Volynets et al. also confirmed that intestinal permeability and endotoxin 
Figure 1. The roles gut microbiota play in liver steatosis. LPS: lipopolysaccharide; SCFAs: short-chain
fatty acids; AAA: aro atic amino acids; BCAA: branched-chain amino acids; EtOH: ethanol; FXR:
farnesoid X receptor; TGR5: transmembrane G protein-coupled receptor 5; GPR: G protein-coupled
receptor; TMAO: trimethylamine-N-oxide; VLDL-C: very-low-density lipoprotein cholesterol; ROS:
Reactive oxygen species; TNF-α: tumor necrosis factor-alfa; IFN- γ: Interferon-gamma; IL-1β:
interleukin 1beta; IL-6: interleukin 6; IL-8: interleukin 8; TLR: toll-like receptor; NAFLD: Non-alcoholic
fatty liver disease.
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2.1. Interplay with Intestinal Microbiota and the Host Immune System
Many factors such as obesity, diet, alcohol intake infection, and medication, can affect the
microbiome and result in impaired intestinal integrity, intestinal bacterial overgrowth, bacterial
translocation, and lipopolysaccharide (LPS) releasing. The subsequent endotoxemia enters the liver
through the portal circulation which induces inflammatory cytokines releasing, resulting in liver injury
that may contribute to NAFLD [30]. Miele et al. indicated that NAFLD patients have a reduced
expression of ZO-1 (zona occludens 1), a major tight junction protein, which results in higher intestinal
permeability [31]. Volynets et al. also confirmed that intestinal permeability and endotoxin levels
in plasma were significantly higher in NAFLD patients [32]. Similar results were also found in the
pediatric population when Giorgio et al. reported that the severity of intestinal permeability correlates
with the severity of NAFLD [33]. NAFLD patients also presented with higher rates of small intestinal
bacterial overgrowth (SIBO) which correlated with the severity of steatosis [31]. Impaired integrity of
the gut barrier, bacterial overgrowth, and bacterial translocation could also allow bacterial endotoxin
to pass to the liver. Lipopolysaccharides (LPS) stimulate Kupffer cells via activating toll-like receptors
(TLRs). These TLRs are pattern recognition receptors that recognize pathogen-associated molecular
patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and are inactive in healthy
liver cells. Once the intestinal barrier is disrupted and endotoxemia circulates via the liver-gut through
the gut-liver axis resulting in increased levels of PAMPs and DAMPs that bind with TLRs (TLR2,
TLR4, TLR5, TLR9, etc.), the inflammatory cascade of releasing inflammatory cytokines (TNF-α, IL-8,
IL1β) could be initiated, and lipid accumulation and cell death in hepatocytes could be stimulated
leading to NAFLD, NASH, and cirrhosis [34–38]. Dysbiosis also plays a critical role in the weakening
of mucosal immunity in a NAFLD host. Jiang et al. showed that, in the context of dysbiosis, CD4- and
CD8-positive cell numbers are decreased in the duodenal mucosa lamina propria and levels of TNF-α,
IL-6, and IFN-γ are increased in the NAFLD group [39].
2.2. Crosstalk between Intestinal Microbiota and Metabolite
2.2.1. Bile Acids
Bile acid homeostasis is regulated by GM. The microbiome is involved in the synthesis of primary
bile acids, cholic acid and chenodeoxycholic acid, by regulating the expression of bile acid synthesis
enzymes. GM also affects other bile acid metabolism processes, includes conjugation in the liver,
reabsorption in the terminal ileum, deconjugation in the small intestine, conversion to secondary bile
acids (lithocholic acid and deoxycholic acid) in the colon, and enterohepatic circulation, by affecting
related enzymes or transporters expression or activity [20]. The disruption of any step in bile acid
metabolism could have pathophysiologic impact. Altered bile acid metabolism results in metabolic
and immune effects that contribute to NAFLD [20,40–42]. Bile acids can regulate metabolism and
inflammation through the farnesoid X receptor (FXR) and transmembrane G protein-coupled receptor
5 (TGR5). FXR is predominantly activated by primary bile acids whereas TGR5 is predominantly
activated by secondary bile acids [43,44].
In terms of metabolic effect, FXR inhibits de novo lipogenesis, increases fatty acid oxidation,
regulates the gene expression involved in triglyceride homeostasis that reduces steatosis and
downregulates gluconeogenesis. FXR also upregulates hepatic glycogen synthesis and regulates
the expression of glucose transporter 4 (GLUT-4) and glucagon-like peptide 1 (GLP-1) which affects
the insulin sensitivity that is closely linked to NAFLD [43]. TGR5 also affects glucose hemostasis via
inducing GLP-1 secretion which increases energy expenditure and attenuates diet-induced obesity [45].
In terms of immunologic effect, bile acids help maintain intestinal barrier integrity to protect
against the GM-related inflammatory cascades in the liver [43]. Bile acids can also decrease hepatic
inflammation and fibrosis via FXR and TGR5 signaling pathways [46]. A few bile acid analogs
have functioned as FXR or TGR5 agonists (INT-767, WAY-362450) showing that they can reduce
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pro-inflammatory gene expression and increase monocyte and IL-10 production to improve hepatic
inflammation, steatosis, and fibrosis [47,48].
2.2.2. Short-Chain Fatty Acids (SCFAs)
SCFAs are primarily composed of acetate, propionate, and butyrate, which are microbial
fermentation products that are found in the colon when a human lacks the enzymatic capacity
to digest certain foods (mainly complex carbohydrates and small portions of amino acids). Most
SCFAs are absorbed in the colon; however, 5–10% of SCFAs are not utilized and are excreted in the
feces [20,49]. Like bile acids, SCFAs also have metabolic and immunologic effects related to NAFLD.
From a metabolic perspective, SCFAs reduce hepatic cholesterol and fatty acid synthesis while
increasing hepatic lipid oxidation [50–52] SCFAs predominantly act on the G protein-coupled receptors
GPR-41 and GPR-43, which are widely distributed in the gut enteroendocrine L cells, white adipose
tissue, skeletal muscles, and the liver [20]. These L cells release glucagon-like peptides that directly act
on hepatocytes by activating genes involved in fatty acid β-oxidation and insulin sensitivity which are
both closely linked to NAFLD [53]. In contrast to long-chain fatty acids (LCFAs) that need carnitine
shuttle to reach the mitochondrial interior, SCFAs could permeate the inner mitochondrial membrane in
carnitine-independent mode. Besides, SCFAs exert weaker protonophoric effects in mitochondria and
cause less disruption to the electron transport in the respiratory chain compared with LCFAs. These
unique features make SCFAs important in lipogenesis, fatty acids oxidation, and ROS genesis [54].
From an immune perspective, SCFAs have an immune regulatory effect and play a complicated
role in Treg cell differentiation via inhibiting the histone deacetylase and GPR-43 pathway. SCFAs have
anti-inflammatory effects by reducing migration and proliferation of immune cells (T cells, neutrophil,
macrophage, monocyte cells), reducing many types of pro-inflammatory cytokines (tumor necrosis
factor-alpha, monocyte chemotactic protein-1, etc), and up-regulating anti-inflammatory cytokine
prostaglandin E2 [55–58].
2.2.3. Aromatic Amino Acid Derivatives and Branched-Chain Amino Acids
A novel class of bacterial metabolites derived from aromatic amino acids (AAA) includes
tryptophan, phenylalanine, and tyrosine have recently received attention and have been considered as
factors in development of NAFLD [59,60].
Tryptophan-derived bacterial metabolites are composed of indole, indole-3-propionic acid,
indole-3-acetic acid, indole-3-aldehyde, tryptamine, and 3-methylindole. Among them, indole is the
main component [61]. These compounds maintain intestinal integrity, reduce bacterial translocation,
prevent the release of microbiota-derived components, and limit inflammatory cascades [59,60]. Oral
administration of indole can reduce the expression of key genes and proteins in the LPS-induced
pro-inflammatory signaling pathway, and it has also been shown to prevent LPS-induced alterations
of the cholesterol metabolism in mouse models [62]. Indole-3-acetate is also found to have similar
protective hepatic effects that attenuate inflammatory responses and reduce lipid accumulation in
hepatocytes via the aryl hydrocarbon receptor (AhR) pathway [63].
Phenylalanine-derived bacterial metabolites are composed of phenylacetic acid, phenylpropionic
acid, and benzoic acid [64]. Hoyles et al. found that plasma phenylacetic acid (PAA) levels are
positively associated with steatosis severity in a morbidly obese women cohort (n = 56) and mice
treated with PAA for 2 weeks had significantly increased triglyceride accumulation. PAA was also
associated with altered gene expression involved in lipid and glucose metabolism [65].
Branched-chain amino acids (BCAA) including valine, leucine, and isoleucine, are another class
of metabolites that received attention in a recent hepatic steatosis study. There is crosstalk about the
relationship between microbiome, host gene expression and BCAA hepatic metabolism [65]. The BCAA
biosynthesis upregulated in the context of obesity and insulin resistance [66,67]. There is also a positive
correlation between hepatic steatosis and plasma and urine BCAA levels. PAA can also significantly
increase hepatic BCAA utilization which can synergetically facilitate hepatic lipid accumulation [65].
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2.2.4. Choline
Choline metabolism is disrupted in the context of dysbiosis and deficiency in choline has
been associated with NAFLD. Dysbiosis has the ability to metabolize choline to trimethylamine
(TMA) which is further oxidized by hepatic flavin containing monooxygenases and converted to
trimethylamine-N-oxide (TMAO) [68]. This process has two effects: (1) choline levels are reduced;
(2) TMAO levels are increased.
Choline plays critical role in the process of very-low-density lipoprotein VLDL synthesis and
facilitates hepatic lipid exportation. Thus choline deficiency results in triglyceride accumulation
in hepatocytes [69]. A small human case study indicated that long-term total parenteral nutrition
(TPN) without choline supplementation induced hepatic steatosis. After receiving parenteral nutrition
solutions containing choline chloride for 6 weeks, the hepatic steatosis of subjects (4/4) resolved
ultimately [70]. TMAO also increases insulin resistance, promotes inflammation and oxidative
stress [71,72]. A clinical study revealed that the higher serum levels of TMAO correlated with greater
severity of NAFLD [68].
2.2.5. Microbial Synthesis of Ethanol
NAFLD patients have been noted to have a higher level of serum ethanol, even with the absence of
alcohol consumption. Nair et al. indicated the presence of ethanol in the breath of obese females with
NASH without alcohol ingestion [73]. Zhu et al. indicated that NASH patients exhibited significantly
elevated blood ethanol levels compared with their lean or obese non-NASH counterparts, along with
an increased abundance of ethanol-producing bacteria [23]. Similarly, Volynets et al. showed that
NAFLD patients have an increased formation of endogenous ethanol in the context of dysbiosis [74].
The accumulation of endogenous alcohol from an increased abundance of alcohol-producing
bacteria subsequently results in significant amounts of free radicals and reactive oxygen that cause
mitochondrial dysfunction, hepatic cellular inflammation and injury [23,75,76]. Other mechanisms
that ethanol plays a role in and that contribute to NAFLD development include, downregulating tight
junction expression, up-regulating de novo lipogenesis, decreasing fatty acid oxidation, and reducing
very low density lipoprotein (VLDL) exportation from the liver [20].
2.3. Energy Extraction and Consumption Balance Disrupted by GM
GM is thought to alter the energy influx and expenditure which may contribute to NAFLD
development. Turnbaugh et al. conducted a study with a cohort of 154 obese and lean twins and
found that in obese humans, the GM-enriched phosphotransferase system is involved in the microbial
processing of carbohydrates, which yields an enhanced capacity to extract calories from the diet [77].
Additionally, the microbiome also altered the host’s energy expenditure via metabolic products
such as bile acids and SCFAs. As mentioned earlier, dysbiosis can alter the level of bile acids and
SCFAs and ultimately affect energy extraction and expenditure. It has been found that bile acids
can increase whole-body energy expenditure and energy consumption via the activation of brown
adipose tissue [78]. SCFAs themselves can provide an energy source for different cell types and tissues.
Butyrate can be utilized by colonocytes as an energy substrate, whereas acetate and propionate can be
utilized as substrates in the process of glucose and fatty acid synthesis, respectively [79]. Canfora et al.
infused SCFA mixtures (either acetate, butyrate, or propionate) into the colon of overweight/obese men.
The SCFAs mixture increased fat oxidation, energy expenditure, and attenuated fasting free glycerol
concentrations compared with the placebo group [80].
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3. Clinical Application of Probiotics and Synbiotics in NAFLD/NASH Patients
Given the correlation between dysbiosis and liver damage, the growing burden of NAFLD, and
lacking effective pharmacologic interventions, restructuring GM to reverse dysbiosis seems like a
potential therapeutic strategy. Probiotics are non-pathogenic, live microorganisms that provide a
health benefit to the host by modifying GM when delivered in sufficient quantities [81]. The most
frequently mentioned probiotics in recent clinical trials are Lactobacilli, Streptococci, and Bifidobacteria.
Prebiotics are non-digestible carbohydrates that can be fermented by bacteria and subsequently change
GM composition and activity to promote health benefits [82]. Synbiotics refer to the combination of
prebiotics and probiotics.
Probiotics and synbiotics can normalize GM and reverse dysbiosis, which could potentially
benefit NAFLD patients [83]. Multiple experimental trials have shown probiotics to have significant
therapeutic effects in fatty liver mice models. The trials showed that administrating probiotics to
high-fat-diet fed mice could prevent the onset of hepatic steatosis and improve hepatic steatosis and
fibrosis. The protective effects have multiple mechanisms including reducing hepatic lipid deposition,
decreasing endotoxemia, reducing oxidative stress, anti-inflammatory effects through the modulation
of nuclear factor kappa B (NF-κB) and tumor necrosis factor (TNF), and antifibrotic effects through
the modification of transforming growth factor-beta (TGF-β) and collagen expression [84–88]. These
preclinical studies suggest that probiotics therapy could be a potential pharmacologic intervention for
NAFLD patients, though the animal model have their limitations. For example, mice are germ-free
animals and the intestine bacterial composite and abundance are different from that of a human.
Most human clinical trials conducted to study the therapeutic effect of probiotics/synbiotics in
NAFLD patients have been conducted over the past 10 years and are small scale with mixed clinical
outcomes. However, the overall outcome indicates that probiotics/synbiotics could be a promising
therapeutic strategy for the NAFLD population. Table 1 summarizes 26 randomized controlled trials
(RCT) that compared probiotics and/or synbiotics versus placebo in NAFLD patients from January
2010to June 2019 in [69,89–113].
3.1. Biochemistry Evaluation
Most of the clinical trials in Table 1 include serum aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) level changes to assess the effects of probiotics or synbiotics on liver function.
A double-blind RCT enrolled 30 patients with NAFLD, thehe intervention group received 3 months
of a combination of Lactobacillus bulgaricus and Streptococcus thermophilus (500 million per day) and
had significant AST and ALT improvement [89]. Similarly, in a 72 NAFLD patients double-blinded
RCT, Nabvi et al. utilized probiotic yogurt (300 g/day) containing Lactobacillus acidophilus La5 and
Bifidobacterium lactis Bb12 as an intervention for 8 weeks. They concluded that probiotics could
significantly improve AST and ALT in NAFLD patients when compared with the placebo group [96].
Shavakhi et al. [92] used probiotics capsules (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus
rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, and Streptococcus
thermophilus) plus metformin 1000mg per day as an intervention.
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Table 1. Summary of major randomized controlled trials using probiotics or synbiotics therapy for NAFLD/NASH.
Study
Design/Population
(N = Included in the Trial) Bacterial Species Duration
Main Outcome Related to NAFLD
Serology Imaging or Biopsy
Aller et al. [89], 2011 Double-blind RCT/NAFLD(N = 28)
Lactobacillus bulgaricus
Streptococcus thermophilus 3 months
(↓) ALT, AST, GGT (-) Anthropometric
parameters and cardiovascular risk
factors
N/A
Vajro et al. [90], 2011
Double-blind RCT/NAFLD obese
children
(N = 20)
Lactobacillus rhamnosus 8 weeks
(↓) ALT
(-) BMI, TNF-α,
peptidoglycanpolysaccharide antibody
N/A
Malaguarnera et al. [91], 2012 RCT/NASH(N = 66)
Bifidobacterium longum
+
Prebiotics (Fructo-oligosaccharides)
24 weeks
(↓) AST, LDL-C, CRP, TNF-α,
endotoxin, HOMA-IR
(-) ALT, bilirubin, HDL-C, TC, TG,
glucose, insulin, C-peptide, BMI
The liver biopsy indicated that
steatosis and NASH activity improved
Shavakhi et al. [92], 2013
Double-blind RCT/NASH on
metformin
(N = 64)
Lactobacillus acidophilus
Lactobacillus casei
Lactobacillus rhamnosus
Lactobacillus bulgaricus
Bifidobacterium breve
Bifidobacterium longum
Streptococcus thermophilus
6 months (↓) ALT, AST, TG, TC, BMI(-) FBS
Grading of steatosis based on US
measurement improved
Wong et al. [93], 2013 RCT/NASH(N = 20)
Lactobacillus plantarum, Lactobacillus deslbrueckii
Lactobacillus acidophilus Lactobacillus rhamnosus
Bifidobacterium bifidum
6 months
(↓) ALT
(-) AST, BMI, waist circumference,
glucose, and lipid levels
Proton-magnetic resonance
spectroscopy-measured that
intrahepatic triglyceride content
(IHTG) improved
Alisi et al. [94], 2014 Double-blind RCT/NAFJD children(N = 44)
Streptococcus thermophilus
Bifidobacterium breve
Bifidobacterium longum Bifidobacterium infantis
Lactobacillus acidophilus Lactobacillus plantarum
Lactobacillus casei Lactobacillus bulgaricus
4 months
(↓) BMI
(↑) GLP-1, activated GLP-1
(-) ALT, triglycerides, HOMA
Grading of steatosis based on US
measurement improved
Eslamparast et al. [95], 2014 Double-blind RCT/NAFLD withlifestyle modification (N = 52)
Lactobacillus casei
Lactobacillus rhamnosus
Lactobacillus acidophilus
Lactobacillus bulgaricus
Bifidobacterium breve
Bifidobacterium longum
Streptococcus thermophilus
+ prebiotic
(fructo-oligosaccharide)
28 weeks (↓) ALT, AST, CRP, TNF-α, NF-κB p65(-) BMI
Transient elastography- measured
fibrosis score improved
Nabvi et al. [96], 2014 Double-blind RCT/NAFLD (N = 72) Lactobacillus acidophilusBifidobacterium lactis 8 weeks
(↓) ALT, AST, TC, LDL-C
(-) Glucose, TG, HDL-C N/A
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Table 1. Cont.
Study
Design/Population
(N = Included in the Trial) Bacterial Species Duration
Main Outcome Related to NAFLD
Serology Imaging or Biopsy
Miccheli et al. [97], 2015 Triple-blind RCT/NAFLD children(N = 31)
Streptococcus thermophilus
Bifidobacterium breve
Bifidobacterium longum Bifidobacterium infantis
Lactobacillus acidophilus Lactobacillus plantarum
Lactobacillus casei Lactobacillus bulgaricus
4 months
(↓) AST,
total and active GLP-1, BMI
(-) ALT, TG, TC, HDL-C, LDL-C,
glucose, insulin
Grading of steatosis based on US
measurement improved
Asgharian et al. [98], 2016 Double-blind RCT/NAFLD (N = 80)
Lactobacillus casei
Lactobacillus acidophilus
Lactobacillus rhamnosus
Lactobacillus bulgaricus
Bifidobacterium breve
Bifidobacterium longum
Streptococcus thermophilus
+ prebiotic (fructo-oligosaccharide)
8 weeks Prevent ASL and ALT elevation(-) CRP, BMI
Grading of steatosis based on US
measurement improved
Ferolla et al. [99], 2016 RCT/NASH(N = 50)
Lactobacillus reuteri
+
prebiotic (inulin)
3 months
(↓) BMI
(-) AST, ALT, ALP, GGT, TC, TG,
HDL-C, VDL-C, LPS, and intestinal
permeability measured by
lactulose/mannitol urinary excretion
MRI-PDFF- measured steatosis
improved but liver fibrosis had no
significant change
Sepideh et al. [100], 2016 Double-blind RCT/NAFLD (N = 42)
Lactobacillus casei
Lactobacillus acidophilus
Lactobacillus rhamnosus
Lactobacillus bulgaricus
Bifidobacterium breve
Bifidobacterium longum
Streptococcus thermophilus
8 weeks (↓) IL-6, FBS, insulin, insulin resistance(-) TNF-alpha N/A
Abdel et al. [101], 2017 RCT/NASH with obesity(N = 30) Lactobacillus acidophilus 1 month
(↓) ALT, AST
(-) TG, TC, FBS Bilirubin, HDL-C N/A
Behrouz et al. [102], 2017 Double-blind RCT/NAFLD(N = 89)
Lactobacillus casei
Lactobacillus rhamnosus
Lactobacillus acidophilus
Bifidobacterium longum
Bifidobacterium breve
12 weeks (↓) Leptin, insulin, and HOMA-IR(-) Adiponectin, FBS N/A
Ekhlasi et al. [103], 2017 Double-blind RCT/NAFLD withVitamin E (N = 60)
Lactobacillus casei
Lactobacillus rhamnosus Stretococcus thermophilus
Bifidobacterium breve Lactobacillus acidophilus
Bifidobacterium longum Lactobacillus bulgaricus
+
prebiotic (fructo-oligosaccharide)
8 weeks
(↓) ALT, AST, ALP, sytolic BP,
malondialdehyde, TNF-alpha
(-) Diastolic Blood Pressure, nitric
oxide, BMI
N/A
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Table 1. Cont.
Study
Design/Population
(N = Included in the Trial) Bacterial Species Duration
Main Outcome Related to NAFLD
Serology Imaging or Biopsy
Famouri et al. [104], 2017 Triple-Blind RCT/NAFLD obesechildren (N = 64)
Lactobacillus acidophilus
Bifidobacterium lactis
Bifidobacterium bifidum
Lactobacillus rhamnosus
12 weeks
(↓) ALT, AST, cholesterol, triglycerides,
LDL-C, and waist circumference
(-) BMI, weight
Grading of steatosis based on US
measurement improved
Manzhalii et al. [105], 2017
RCT/NASH with
low-fat/low-calorie diet
(N = 75)
Lactobacilli
Bifidobacteria
Streptococcus thermophilus
12 weeks (↓) ALT, BMI and cholesterol(-) GGT
Liver stiffness based on US
measurement improved
Mofidi et al. [106], 2017 Double-blind RCT/NAFLD(N = 50)
Lactobacillus acidophilus
Lactobacillus casei
Lactobacillus rhamnosus
Lactobacillus bulgaricus
Bifidobacterium breve
Bifidobacterium longum
Streptococcus thermophilus
+ prebiotic
(fructo-oligosaccharide)
28 weeks
(↓) AST, ALT, GGT, glucose,
triglyceride, Total cholesterol, CRP,
NF-κB p65
(-) HDL-C, LDL-C, TNF-α
Transient elastography-measured
hepatic steatosis and fibrosis improved
Bakhshimoghaddam et al.
[107], 2018 RCT/NAFLD (N = 102)
Bifidobacterium animalis
+ prebiotic (inulin) 24 weeks (↓) AST, ALT, GGT, ALP, TG, TC
Grading of steatosis based on US
measurement improved
Javadi et al. [108], 2018 Double-blind RCT/NAFLD (N = 75)
Bifidobacterium longum
Lactobacillus acidophilus
+ prebiotic (inulin)
3 months
(↓) CRP, TNF-α, BMI
(↑) TAC
(-) IL-6, MDA
N/A
Kobyliak et al. [109], 2018
Double-blind RCT/NAFLD with
type II DM
(N = 48)
Bifidobacterium
Lactobacillus
Lactococcus
Propionibacterium
Acetobacter
+ omega-3 fatty acids
8 weeks
(↓) GGT, TG, TC, VLDL-C, TNF-α, IL-6
(-) AST, ALT, LDL-C, HDL-C, INF-γ,
IL-1β, IL-8
Shear Wave Elastography-measured
fatty liver index improvement but no
significant change in liver stiffness
Kobyliak et al. [110], 2018 Double-blind RCT/NAFLD withtype II DM (N = 58)
Bifidobacterium
Lactobacillus
Lactococcus
Propionibacterium
Acetobacter
8 weeks
(↓) AST, GTT, TNF-α, IL-6
(-) ALT, TC, TG, VLDL-C, HDL-C,
IL-1β, IL-8, IFN- γ
Shear Wave Elastography-measured
fatty liver index improvement but no
significant change in liver stiffness
Sayari et al. [111], 2018 RCT/NAFLD with sitagliptin(N = 138)
Lactobacillus casei Lactobacillus rhamnosus
Lactobacillus acidophilus
Lactobacillus bulgaricus Bifidobacterium breve
Bifidobacterium longum
Streptococcus thermophilus
+ prebiotic
(fructo-oligosaccharide)
16 weeks (↓) AST, TC, LDL-C, FBS(-) ALT, HDL-C, TG, BMI N/A
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Table 1. Cont.
Study
Design/Population
(N = Included in the Trial) Bacterial Species Duration
Main Outcome Related to NAFLD
Serology Imaging or Biopsy
Wang et al. [112], 2018 Double-blind RCT/NAFLD (N =200)
Bifidobacterium Lactobacillus
Enterococcus
Bacillus subtilis
1 month
(↓) AST, ALT, TC, TG, glucose,
VLDL-C, TNF-α
(↑) High molecular weight adiponectin
(-) HDL-C
Grading of steatosis based on US
measurement showed no significant
difference
Ahn et al. [113], 2019
Double-blind RCT/NAFLD with
obesity
(N = 68)
Lactobacillus acidophilus
Lactobacillus rhamnosus
Lactobacillus paracasei
Pediococcus pentosaceus Bifidobacterium lactis
Bifidobacterium breve
12 weeks
(↓) TG
(-) AST, ALT, TC, HDL-C, glucose,
insulin, TNF-α, IL-6, LPS
MRI-PDFF-measured intrahepatic fat
fraction (IHF) and mean IHF reduced
compared with control, but no
significant change in liver stiffness
Duseja et al. [69], 2019 Double-blind RCT/NAFLD (N = 30)
Lactobacillus paracasei
Lactobacillus plantarum
Lactobacillus acidophilus
Lactobacillus delbrueckii
subsp. bulgaricus
Bifidobacterium longum
Bifidobacterium infantis
Bifidobacterium breve
Streptococcus thermophilus
1 year
(↓) ALT, ALP, leptin, TNF-α, and LPS
(-) AST, Bilirubin, Adiponectin, IL-1β,
IL-6
The biopsy indicated hepatocyte
ballooning, NAS score and fibrosis
improved, but not steatosis or lobular
inflammation
NAFLD: Non-alcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; ALT: alanine transaminase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; ALP:
alkaline phosphatase; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; FBS: fasting serum glucose; GLP-1:
glucagon-like peptide 1; BMI: body mass index; LPS: Lipopolysaccharides; CRP: C reactive protein; TNF-α: tumor necrosis factor-alfa; NF-κB p65: nuclear factor kappa-light-chain-enhancer
of activated B cells subunit p65; IFN- γ: Interferon-gamma; IL-1β: interlukin 1beta; IL-6: interleukin 6; IL-8: interleukin 8; MDA: malondialdehyde; TAC: total antioxidant capacity; NAS:
NAFLD activity score; HOMA-IR: homeostasis model assessment of insulin resistance; US: ultrasonography; MRI-PDFF: magnetic resonance imaging–derived proton density fat fraction;
IHF: intrahepatic fat fraction.
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When compared with the control group who only take metformin 1000mg per day, it was found
that the probiotics with metformin synergically improved liver aminotransferases in NASH patients.
A few other RCTs that utilized different species of probiotics also revealed that probiotics could
improve either AST or ALT, or both transaminases in NAFLD patients [69,91,93,97,101,105,110,112].
Four recent synbiotics RCTs utilized a combination of probiotics (Lactobacillus acidophilus, Lactobacillus
casei, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, and
Streptococcus thermophilus) plus prebiotics (either fructooligosaccharide or inulin) and concluded that
synbiotics supplements can also benefit liver function [95,103,106,111].
Similar to the adult population, pediatric clinical trials also revealed that probiotics and synbiotics
could improve AST and ALT in NAFLD patients. Vajro et al. enrolled 20 pediatric obese NAFLD
patients and offered the intervention group a Lactobacillus rhamnosus strain GG (12 billion CFU/day).
The data indicated a significant decrease in ALT after an 8 weeks trial [90]. Similarly, in a triple blinded
RCT, Famouri et al. enrolled 64 obese children with sonographic NAFLD and the interventional
group received probiotics capsules (Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium
bifidum, and Lactobacillus rhamnosus). The primary outcome indicated that the probiotics group had a
significantly lower mean value of AST and ALT, as well as lower levels of cholesterol, triglycerides,
and LDL-C after a 12 week intervention [104]. Miccheli et al. enrolled 31 pediatric NAFLD patients
with a VSL#3 (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium
infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus)
intervention for 4 months. They concluded that, compared with the placebo group, AST but not ALT
significantly improved [97].
However, not all of the completed trials support the notion that probiotics or synbiotics can
improve liver enzyme levels. For example, Ahn et al. published a trial in 2019 that enrolled 68
adult obese NAFLD patients. The interventional group was treated with a multispecies probiotics
mixture (Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei, Pediococcus pentosaceus,
Bifidobacterium lactis, and Bifidobacterium breve) for 12 weeks. Results revealed that probiotics improved
the intrahepatic fat (IHF) fraction measured by MRI-PDFF but there was no significant improvement of
ALT or AST when compared with the placebo group [113]. Alisi et al. conducted a RCT in 2014, enrolling
22 NAFLD children. The interventional group was treated with probiotics capsules (Streptococcus
thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus,
Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus) for 4 months. However, the trial
failed to reveal any significant liver enzyme improvement when compared with the placebo group [94].
Some synbiotics trials have also failed to show liver enzyme improvement. For instance, Ferolla et al.
conducted an RCT of 50 NASH patients and indicated that synbiotics (Lactobacillus reuteri + inulin)
neither improved liver function nor steatosis [99].
These mixed results also occurred with other serum markers including Gamma-glutamyl
transferase (GGT), alkaline phosphatase (ALP), total cholesterol (TC), triglyceride (TG), low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting serum glucose
(FBS) and inflammatory markers [69,89–113]. Given the pattern of mixed results, Table 2 summarizes the
most recently published meta-analyses of RCTs with probiotic/synbiotic treatment for NAFLD/NASH
populations [114–118].
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Table 2. Summary of recent meta-analysis of RCTs with probiotics/synbiotics therapy for
NAFLD/NASH patients.
Study Population Study Period Conclusions
Loman et al. [114], 2018
Included 25 studies (most are RCT):
Among them, 9 studies used prebiotics,
11 studies used probiotics, and 7 studies
used synbiotics. 1309 patients
were included.
Up to December 14, 2017
Microbial therapies significantly
reduced AST and ALT, but not CRP.
The results of serum cholesterol and
LDL-C are mixed among prebiotics,
probiotics, and synbiotics.
Khan et al. [115], 2019 Included 12 probiotics/synbiotics RCTsfor NAFLD. 748 patients were included. Up to June 10, 2018
Probiotics/synbiotics were associated
with a significant improvement in ALT,
AST, and liver fibrosis score graded by
fibroscan. There was a reduction in CRP
with synbiotics. The TNF-α, LDL-C, TG,
and TC significantly improved with
synbiotics but not with probiotics in a
subgroup analysis. There were no
significant changes in HDL-C,
HOMA-IR, or FBS in either group.
Koutnikova et al. [116], 2019
Included 105 articles with 111 RCTs
representing 6826 subjects (includes
metabolic syndrome, type II DM, and
NAFLD patients). Among them, about
658 patients had NAFLD.
January 1990 to June 2018
In subjects with fatty liver diseases,
probiotics reduced AST and ALT, but
not GGT.
Liu et al. [117], 2019
Included 15 probiotics and synbiotic
RCTs, involving 782 patients with
NAFLD.
Up to April 2018
Probiotics and synbiotics
supplementation could significantly
improve AST, ALT, TG, TC, HDL-C,
LDL-C, homeostasis model
assessment-insulin resistance, TNF-α,
liver steatosis, and liver stiffness.
However, probiotics and synbiotics
could not ameliorate BMI, waist
circumference, or FBS.
Sharpton et al. [118], 2019
Included 21 RCTs (1252 participants)
with NAFLD. 9 trials evaluated
probiotics and 12 trials
evaluated synbiotics.
January 1, 2005 to December
1, 2018
Probiotics/synbiotics could improve
AST and ALT. Probiotics/synbiotics
were also associated with hepatic
steatosis improvement when graded
with ultrasound. Last,
probiotics/synbiotics were associated
with liver stiffness improvement when
measured by elastography, although
analyses showed heterogeneity.
Probiotics, but not synbiotics, were
associated with a significant reduction
in body mass index.
NAFLD: Non-alcoholic fatty liver disease;DM: diabetes mellitus; ALT: alanine transaminase; AST: aspartate
aminotransferase; GGT: gamma-glutamyl transferase; LDL-C: low-density lipoprotein cholesterol; HDL-C:
high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; FBS: fasting serum glucose; BMI:
body mass index; CRP: C reactive protein; TNF-α: tumor necrosis factor-alfa; HOMA-IR: homeostasis model
assessment of insulin resistance.
All of the meta-analyses listed indicated that microbial therapies are associated with a significant
improvement in ALT and AST [114–118]. Regarding the other serum markers, Liu et al. included 15
probiotics and synbiotics RCTs involving 782 patients with NAFLD up to April 2018. They found that
probiotic and synbiotic supplementation is associated with a significant reduction in TG, TC, HDL-C,
LDL-C, and TNF-α levels [117]. Koutnikova et al. included 111 RCTs representing 6826 subjects with
metabolic syndrome, type II DM, and NAFLD. Subgroup analysis of NAFLD patients did not indicate
that probiotics significantly reduced GGT [116]. Khan et al. included 12 probiotics and synbiotics
RCTs up to June 2018. They concluded that a reduction in CRP occurred in synbiotics trials. However,
TNF-α, LDL-C, TG, and TC only significantly improved in the synbiotics but not probiotics group, and
HDL-C and FBS did not significantly change in either group [115]. Of note, serologic markers have
high variability and not directly reflect the disease progression in context of NAFLD. Thus, there are
emerging studies utilized the imaging modalities to evaluate NAFLD clinical outcome outline below.
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3.2. Imaging Modalities to Assess Hepatic Steatosis and Stiffness
Several trials included imaging evaluation as part of clinical outcomes to assess the effect of
probiotics and synbiotics on hepatic steatosis, fibrosis, and liver stiffness. Ultrasonography (US)
is the most commonly used imaging modality for liver morphology study. The research teams of
Shavakhi [92], Miccheli [97], Asgharian [98], Famouri [104], and Bakhshimoghaddam et al. [107]
reported that US-measured steatosis significantly improved in adult patients who took probiotics and
synbiotics supplements. Alisi et al. revealed a similar efficacy of probiotics improving US-measured
hepatic steatosis in pediatric NAFLD patients [94]. Manzhalii et al. conducted an RCT with 75 enrolled
NASH patients on low-fat/low-calorie diets. Probiotics (Lactobacilli, Bifidobacteria, and Streptococcus
thermophilus) were administered in the intervention group for 12 weeks. US-measured liver stiffness
improved in the probiotics group compared with the control group [105]. However, in 2018, Wang et al.
got different results in a double-blind RCT with 200 NAFLD patients. The experimental group received
Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus subtilis for a 1-month duration and there was no
significant difference in the severity of steatosis measured by US [112]. The likely explanation was
that the intervention duration was relatively shorter. Also, as a measurement tool, US has technical
limitations when it comes to accurately evaluating the severity of hepatic steatosis.
Over recent years, elastography-based imaging techniques have received increased attention in the
field of non-invasive assessment for organ tissue, especially the liver. These techniques utilize soft tissue
elasticity changes in various pathologies to yield qualitative and quantitative analyses and are superior
to US in assessing the severity of liver steatosis, fibrosis, and cirrhosis [119]. Eslamparast et al. conducted
a double-blind RCT that enrolled 52 NAFLD patients with a synbiotics (probiotics cocktail - Lactobacillus
casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve,
Bifidobacterium longum, Streptococcus thermophilus, and the prebiotic fructooligosaccharide) intervention
for 28 weeks and the elastography-measured fibrosis score improved [95]. Mofidi et al. applied the
same intervention as the Eslamparasts team, enrolling 50 NAFLD patients who took part in a transient
elastography evaluation. Results indicated that synbiotics are associated with hepatic steatosis and
fibrosis improvement which is consistent with the results of Eslamparasts team [106]. Kobyliak
conducted two double-blind RCTs in 2018. One enrolled 58 NAFLD with type 2 diabetes patients.
The intervention team received probiotics called “Symbiter” which is composed of Bifidobacterium,
Lactobacillus, Lactococcus, Propionibacterium, and Acetobacter for 8 weeks and utilized shear wave
elastography (SWE) to measure hepatic fibrosis. The trial concluded that probiotics can improve
fatty liver index but that there is no significant change in liver stiffness graded by SWE [110]. His
team conducted another double-blind RCT that enrolled 48 NAFLD with type 2 diabetes patients.
The intervention team received a combination of the same probiotics mentioned above plus Omega-3
fatty acids called “Symbiter Omega”. After an 8-week intervention, results revealed similar significantly
reduce liver steatosis but not liver stiffness [109].
Magnetic resonance imaging–derived proton density fat fraction (MRI-PDFF) is another novel
modality that, over recent years, has been used to evaluate hepatic steatosis. The feature of accurately
measuring the distribution of intrahepatic fat fraction (IHF) across the liver in seconds has led to its
rising popularity in NAFLD research [120]. A few trials utilized this technique to analyze the efficacy
of probiotics/synbiotics in steatosis, for example, Ahn et al. concluded that a probiotics therapy group
had a reduced mean value IHF compared with the control group, however, there was no significant
change in liver stiffness between the probiotics and control groups [113]. Ferolla et al. reported
that MRI-PDFF-measured steatosis was reduced in the synbiotics group but there was no significant
change in liver fibrosis [99]. There is only one published RCT that utilized proton-magnetic resonance
spectroscopy to measure intrahepatic triglyceride content (IHTG). Wong et al. conducted a trial with
20 NASH patients. The intervention group was treated with Lactobacillus plantarum, Lactobacillus
deslbrueckii, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Bifidobacterium bifidum for 6 months.
The primary outcome of the RCT is that IHTG decreased from the baseline of 22.6% to 14.9% in the
probiotics group whereas IHTG remained static in the usual care group [93].
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Two large-scale meta-analyses conducted by Sharpton et al. [118] and Liu et al. [117]
indicated that probiotics/synbiotics improved liver stiffness that was measured by elastography,
and probiotics/synbiotics are associated with hepatic steatosis improvement as graded by the US
though analyses showed heterogeneity. Another meta-analysis conducted by Khan et al. indicated
that probiotics/synbiotics are associated with a significant improvement in liver fibrosis score graded
by fibroscan [115].
3.3. Histologic Evaluation
The fact that most probiotics/synbiotics intervention trials lack a liver biopsy to further assess
histological changes in liver steatosis, fibrosis, cirrhosis, and inflammation is a noticeable limitation.
Nevertheless, there are still two RCTs that utilized liver biopsy at the end of clinical trials to
evaluate histological changes after probiotics and synbiotics interventions. Malaguarnera et al.
conducted an RCT that enrolled 66 NASH patients. The study used synbiotics (Bifidobacterium
longum+fructooligosaccharides) as an intervention for 24 weeks and the liver biopsy indicated hepatic
steatosis improvement and reduced NASH activity in the synbiotics group when compared with
the control group [91]. Duseja et al. conducted a double-blind RCT with 30 enrolled NAFLD
patients. The probiotics administered were composed of Lactobacillus paracasei, Lactobacillus plantarum,
Lactobacillus acidophilus, Lactobacillus delbrueckii subsp. bulgaricus, Bifidobacterium longum, Bifidobacterium
infantis, Bifidobacterium breve, and Streptococcus thermophilus. After 1 year of treatment, a liver biopsy
indicated significantly reduced hepatocyte ballooning, NAS score, and fibrosis compared with the
control group. However, there was no significant hepatic steatosis or lobular inflammation difference
between the two groups [69].
3.4. Safety and Tolerability of Probiotics in NAFLD Patients
Probiotics/synbiotics have a relatively safe profile, and historically, probiotics have been widely
used in dairy products without significant safety concerns. The Agency for Healthcare Research
and Quality (AHRQ) released a report in 2011 that extensively reviewed literature regarding the
probiotic safety and adverse event reports. It included six probiotic genera (Lactobacillus, Bifidobacterium,
Streptococcus, Enterococcus, Bacillus, and Saccharomyces) and 622 studies and concluded that the existing
probiotic RCTs reveal no evidence of increased risk. However, due to the lack of assessment and
systematic reporting of adverse events in probiotic intervention studies, AHRQ was not equipped to
clarify the safety of probiotic interventions with confidence [121]. Though clinical trials rarely reported
adverse effects or issues of safety with patients with NAFLD, lacking long-term, post-intervention
follow-up in clinical trials is a setback regarding safety assessment. There are a few case reports of
probiotics having adverse effects such as systemic infections (bacteremia and endocarditis), bowel
ischemia, inflammatory reaction, D-lactic acidosis, and gastrointestinal side effects [122]. Although
microbial therapy seems to be safe, it is necessary to evaluate probiotic- or synbiotic-associated adverse
effects and investigate safety profiles for long-term use.
4. Concluding Remarks
With the rapidly growing incidence and prevalence of NAFLD and lack of effective pharmacological
intervention, there is an urgent need for developing novel medications for treatment. The link between
GM and NAFLD has received increased attention and a growing number of studies have revealed that
the host-gut microbiome interaction and pathophysiology of dysbiosis may promote the development of
NAFLD. Bacterial derivative metabolites, immune-related effects, and energy extraction/consumption
balance disruption might promote NAFLD progression. Therefore, restoring dysbiosis could be a
potential therapeutic strategy for NAFLD, an idea backed by multiple recent probiotics and synbiotics
clinical trials in the specific context of NAFLD and NASH. The literature to date is encouraging and
supports the notion that probiotics/synbiotics may improve transaminase levels, hepatic steatosis,
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and NAFLD activity score. To some extent, probiotics/synbiotics can also reduce proinflammatory
cytokines such as TNF-α and the interleukin family (IL-1, IL-6, IL-8).
Overall, probiotics/synbiotics have a safe profile and are well-tolerated though more safety
evaluations need to be completed in the future. Additionally, the sustainability of the probiotic/synbiotic
protective effect on NAFLD over the long-term is still not clear. In this growing NAFLD epidemic
era, further studies are necessary to more clearly elucidate the efficacy, safety, and sustainability of
probiotics/synbiotics in the management of NAFLD.
Author Contributions: C.X. and D.H.-D. made substantial contributions to the conception or design of the work.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest. Halegoua-DeMarzio is a consultant for Gilead
and Intercept Pharmaceuticals.
References
1. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J.
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American
Association for the Study of Liver Diseases, American College of Gastroenterology, and the American
Gastroenterological Association. Hepatology 2012, 55, 2005–2023. [CrossRef] [PubMed]
2. Farrell, G.C.; Wong, V.W.; Chitturi, S. NAFLD in Asia-as common and important as in the West. Nat. Rev.
Gastroenterol. Hepatol. 2013, 10, 307–318. [CrossRef] [PubMed]
3. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of
nonalcoholic fatty liver disease. Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology
2016, 64, 73–84. [CrossRef]
4. Hashimoto, E.; Yatsuji, S.; Tobari, M.; Taniai, M.; Torii, N.; Tokushige, K.; Shiratori, K. Hepatocellular
carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 2009, 44 (Suppl. 19), 89–95.
[CrossRef]
5. Kodama, K.; Tokushige, K.; Hashimoto, E.; Taniai, M.; Shiratori, K. Hepatic and extrahepatic malignancies in
cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol. Clin. Exp. Res. 2013,
37 (Suppl. 1), E247–E252. [CrossRef]
6. Paranagua-Vezozzo, D.C.; Ono, S.K.; Alvarado-Mora, M.V.; Farias, A.Q.; Cunha-Silva, M.; Franca, J.I.;
Alves, V.A.; Sherman, M.; Carrilho, F.J. Epidemiology of HCC in Brazil: Incidence and risk factors in a
ten-year cohort. Ann. Hepatol. 2014, 13, 386–393. [CrossRef]
7. Yatsuji, S.; Hashimoto, E.; Tobari, M.; Taniai, M.; Tokushige, K.; Shiratori, K. Clinical features and outcomes
of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.
J. Gastroenterol. Hepatol. 2009, 24, 248–254. [CrossRef]
8. Younossi, Z.; Stepanova, M.; Ong, J.P.; Jacobson, I.M.; Bugianesi, E.; Duseja, A.; Eguchi, Y.; Wong, V.W.;
Negro, F.; Yilmaz, Y.; et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular
Carcinoma in Liver Transplant Candidates. Clin. Gastroenterol. Hepatol. 2019, 17, 748–755.e743. [CrossRef]
9. Sangouni, A.A.; Ghavamzadeh, S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a
therapeutic approach. Diabetes Metab. Syndr. 2019, 13, 2917–2922. [CrossRef]
10. Marra, F.; Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 2018,
68, 280–295. [CrossRef]
11. Hardy, T.; Oakley, F.; Anstee, Q.M.; Day, C.P. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease
Spectrum. Ann. Rev. Pathol. 2016, 11, 451–496. [CrossRef]
12. Moran-Ramos, S.; Lopez-Contreras, B.E.; Canizales-Quinteros, S. Gut Microbiota in Obesity and Metabolic
Abnormalities: A Matter of Composition or Functionality? Arch. Med. Res. 2017, 48, 735–753. [CrossRef]
13. Chassaing, B.; Etienne-Mesmin, L.; Gewirtz, A.T. Microbiota-liver axis in hepatic disease. Hepatology 2014,
59, 328–339. [CrossRef]
14. Kamada, N.; Nunez, G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology
2014, 146, 1477–1488. [CrossRef]
Nutrients 2019, 11, 2837 17 of 22
15. Tap, J.; Mondot, S.; Levenez, F.; Pelletier, E.; Caron, C.; Furet, J.P.; Ugarte, E.; Munoz-Tamayo, R.; Paslier, D.L.;
Nalin, R.; et al. Towards the human intestinal microbiota phylogenetic core. Env. Microbiol. 2009,
11, 2574–2584. [CrossRef]
16. Naito, Y.; Kashiwagi, K.; Takagi, T.; Andoh, A.; Inoue, R. Intestinal Dysbiosis Secondary to Proton-Pump
Inhibitor Use. Digestion 2018, 97, 195–204. [CrossRef]
17. Rodriguez, J.M.; Murphy, K.; Stanton, C.; Ross, R.P.; Kober, O.I.; Juge, N.; Avershina, E.; Rudi, K.; Narbad, A.;
Jenmalm, M.C.; et al. The composition of the gut microbiota throughout life, with an emphasis on early life.
Microb. Ecol. Health Dis. 2015, 26, 26050. [CrossRef]
18. Uchiyama, K.; Naito, Y.; Takagi, T. Intestinal microbiome as a novel therapeutic target for local and systemic
inflammation. Pharmcol. Ther. 2019, 199, 164–172. [CrossRef]
19. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome.
Nature 2012, 486, 207–214. [CrossRef]
20. Mouzaki, M.; Loomba, R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver
disease: Rationale and prospects for therapeutic intervention. Ther. Adv. Gastroenterol. 2019, 12. [CrossRef]
21. Mouzaki, M.; Comelli, E.M.; Arendt, B.M.; Bonengel, J.; Fung, S.K.; Fischer, S.E.; McGilvray, I.D.; Allard, J.P.
Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58, 120–127. [CrossRef]
22. Wigg, A.J.; Roberts-Thomson, I.C.; Dymock, R.B.; McCarthy, P.J.; Grose, R.H.; Cummins, A.G. The role of
small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor
alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48, 206–211. [CrossRef]
23. Zhu, L.; Baker, S.S.; Gill, C.; Liu, W.; Alkhouri, R.; Baker, R.D.; Gill, S.R. Characterization of gut microbiomes
in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH.
Hepatology 2013, 57, 601–609. [CrossRef]
24. Knight, R.; Callewaert, C.; Marotz, C.; Hyde, E.R.; Debelius, J.W.; McDonald, D.; Sogin, M.L. The Microbiome
and Human Biology. Ann. Rev. Genom. Hum. Genet. 2017, 18, 65–86. [CrossRef]
25. Del Chierico, F.; Nobili, V.; Vernocchi, P.; Russo, A.; De Stefanis, C.; Gnani, D.; Furlanello, C.; Zandona, A.;
Paci, P.; Capuani, G.; et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese
patients unveiled by an integrated meta-omics-based approach. Hepatology 2017, 65, 451–464. [CrossRef]
26. Boursier, J.; Mueller, O.; Barret, M.; Machado, M.; Fizanne, L.; Araujo-Perez, F.; Guy, C.D.; Seed, P.C.;
Rawls, J.F.; David, L.A.; et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis
and shift in the metabolic function of the gut microbiota. Hepatology 2016, 63, 764–775. [CrossRef]
27. Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease
(NAFLD). Metabolism 2016, 65, 1038–1048. [CrossRef]
28. Gupta, H.; Youn, G.S.; Shin, M.J.; Suk, K.T. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms
2019, 7, 121. [CrossRef]
29. Kho, Z.Y.; Lal, S.K. The Human Gut Microbiome—A Potential Controller of Wellness and Disease.
Front. Microbiol. 2018, 9, 1835. [CrossRef]
30. Bajaj, J.S. The role of microbiota in hepatic encephalopathy. Gut Microbes 2014, 5, 397–403. [CrossRef]
31. Miele, L.; Valenza, V.; La Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Masciana, R.; Forgione, A.;
Gabrieli, M.L.; Perotti, G.; et al. Increased intestinal permeability and tight junction alterations in nonalcoholic
fatty liver disease. Hepatology 2009, 49, 1877–1887. [CrossRef] [PubMed]
32. Lavekar, A.S.; Raje, D.V.; Manohar, T.; Lavekar, A.A. Role of Probiotics in the Treatment of Nonalcoholic
Fatty Liver Disease: A Meta-analysis. Euroasian J. Hepatogastroenterol. 2017, 7, 130–137. [CrossRef] [PubMed]
33. Giorgio, V.; Miele, L.; Principessa, L.; Ferretti, F.; Villa, M.P.; Negro, V.; Grieco, A.; Alisi, A.; Nobili, V. Intestinal
permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease
severity. Dig. Liver Dis. 2014, 46, 556–560. [CrossRef] [PubMed]
34. Miura, K.; Kodama, Y.; Inokuchi, S.; Schnabl, B.; Aoyama, T.; Ohnishi, H.; Olefsky, J.M.; Brenner, D.A.; Seki, E.
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010,
139, 323–334.e327. [CrossRef]
35. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like
receptors. Nat. Immunol. 2010, 11, 373–384. [CrossRef] [PubMed]
36. Miura, K.; Ohnishi, H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
World J. Gastroenterol. 2014, 20, 7381–7391. [CrossRef]
Nutrients 2019, 11, 2837 18 of 22
37. Vijay-Kumar, M.; Aitken, J.D.; Carvalho, F.A.; Cullender, T.C.; Mwangi, S.; Srinivasan, S.; Sitaraman, S.V.;
Knight, R.; Ley, R.E.; Gewirtz, A.T. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like
receptor 5. Science 2010, 328, 228–231. [CrossRef]
38. Szabo, G.; Velayudham, A.; Romics, L., Jr.; Mandrekar, P. Modulation of non-alcoholic steatohepatitis by
pattern recognition receptors in mice: The role of toll-like receptors 2 and 4. Alcohol. Clin. Exp. Res. 2005,
29, 140S–145S. [CrossRef]
39. Jiang, W.; Wu, N.; Wang, X.; Chi, Y.; Zhang, Y.; Qiu, X.; Hu, Y.; Li, J.; Liu, Y. Dysbiosis gut microbiota associated
with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty
liver disease. Sci. Rep. 2015, 5, 8096. [CrossRef]
40. Sarathy, J.; Detloff, S.J.; Ao, M.; Khan, N.; French, S.; Sirajuddin, H.; Nair, T.; Rao, M.C. The Yin and Yang of
bile acid action on tight junctions in a model colonic epithelium. Physiol. Rep. 2017, 5, e13294. [CrossRef]
41. Wegner, K.; Just, S.; Gau, L.; Mueller, H.; Gerard, P.; Lepage, P.; Clavel, T.; Rohn, S. Rapid analysis of bile
acids in different biological matrices using LC-ESI-MS/MS for the investigation of bile acid transformation by
mammalian gut bacteria. Anal. Bioanal. Chem. 2017, 409, 1231–1245. [CrossRef]
42. Wahlstrom, A.; Sayin, S.I.; Marschall, H.U.; Backhed, F. Intestinal Crosstalk between Bile Acids and Microbiota
and Its Impact on Host Metabolism. Cell Metab. 2016, 24, 41–50. [CrossRef] [PubMed]
43. Chavez-Talavera, O.; Tailleux, A.; Lefebvre, P.; Staels, B. Bile Acid Control of Metabolism and Inflammation
in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology 2017,
152, 1679–1694.e1673. [CrossRef] [PubMed]
44. Arab, J.P.; Karpen, S.J.; Dawson, P.A.; Arrese, M.; Trauner, M. Bile acids and nonalcoholic fatty liver disease:
Molecular insights and therapeutic perspectives. Hepatology 2017, 65, 350–362. [CrossRef] [PubMed]
45. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.;
Mataki, C.; Pruzanski, M.; et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab.
2009, 10, 167–177. [CrossRef]
46. Liu, H.; Pathak, P.; Boehme, S.; Chiang, J.Y. Cholesterol 7alpha-hydroxylase protects the liver from
inflammation and fibrosis by maintaining cholesterol homeostasis. J. Lipid Res. 2016, 57, 1831–1844.
[CrossRef]
47. Zhang, S.; Wang, J.; Liu, Q.; Harnish, D.C. Farnesoid X receptor agonist WAY-362450 attenuates liver
inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 2009, 51, 380–388.
[CrossRef]
48. McMahan, R.H.; Wang, X.X.; Cheng, L.L.; Krisko, T.; Smith, M.; El Kasmi, K.; Pruzanski, M.; Adorini, L.;
Golden-Mason, L.; Levi, M.; et al. Bile acid receptor activation modulates hepatic monocyte activity and
improves nonalcoholic fatty liver disease. J. Biol. Chem. 2013, 288, 11761–11770. [CrossRef]
49. Leung, C.; Rivera, L.; Furness, J.B.; Angus, P.W. The role of the gut microbiota in NAFLD. Nat. Rev.
Gastroenterol. Hepatol. 2016, 13, 412–425. [CrossRef]
50. Wright, R.S.; Anderson, J.W.; Bridges, S.R. Propionate inhibits hepatocyte lipid synthesis. Proc. Soc. Exp.
Biol. Med. 1990, 195, 26–29. [CrossRef]
51. Demigne, C.; Morand, C.; Levrat, M.A.; Besson, C.; Moundras, C.; Remesy, C. Effect of propionate on fatty
acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br. J. Nutr. 1995,
74, 209–219. [CrossRef] [PubMed]
52. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota
metabolic interactions. Science 2012, 336, 1262–1267. [CrossRef] [PubMed]
53. Svegliati-Baroni, G.; Saccomanno, S.; Rychlicki, C.; Agostinelli, L.; De Minicis, S.; Candelaresi, C.; Faraci, G.;
Pacetti, D.; Vivarelli, M.; Nicolini, D.; et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid
oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Liver Int. 2011, 31, 1285–1297. [CrossRef] [PubMed]
54. Schonfeld, P.; Wojtczak, L. Short- and medium-chain fatty acids in energy metabolism: The cellular perspective.
J. Lipid Res. 2016, 57, 943–954. [CrossRef] [PubMed]
55. Ohira, H.; Tsutsui, W.; Fujioka, Y. Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for
Inflammation and Atherosclerosis? J. Atheroscler. Thromb. 2017, 24, 660–672. [CrossRef] [PubMed]
56. Smith, P.M.; Howitt, M.R.; Panikov, N.; Michaud, M.; Gallini, C.A.; Bohlooly, Y.M.; Glickman, J.N.; Garrett, W.S.
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013,
341, 569–573. [CrossRef] [PubMed]
Nutrients 2019, 11, 2837 19 of 22
57. Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veeken, J.; deRoos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.;
Coffer, P.J.; et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell
generation. Nature 2013, 504, 451–455. [CrossRef]
58. Usami, M.; Kishimoto, K.; Ohata, A.; Miyoshi, M.; Aoyama, M.; Fueda, Y.; Kotani, J. Butyrate and trichostatin
A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase
prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr. Res. 2008, 28, 321–328.
[CrossRef]
59. Agus, A.; Planchais, J.; Sokol, H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease.
Cell Host Microbe 2018, 23, 716–724. [CrossRef]
60. Roager, H.M.; Licht, T.R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 2018, 9, 3294.
[CrossRef]
61. Jin, U.H.; Lee, S.O.; Sridharan, G.; Lee, K.; Davidson, L.A.; Jayaraman, A.; Chapkin, R.S.; Alaniz, R.; Safe, S.
Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and
antagonist activities. Mol. Pharm. 2014, 85, 777–788. [CrossRef] [PubMed]
62. Beaumont, M.; Neyrinck, A.M.; Olivares, M.; Rodriguez, J.; de Rocca Serra, A.; Roumain, M.; Bindels, L.B.;
Cani, P.D.; Evenepoel, P.; Muccioli, G.G.; et al. The gut microbiota metabolite indole alleviates liver
inflammation in mice. FASEB J. 2018. [CrossRef] [PubMed]
63. Krishnan, S.; Ding, Y.; Saedi, N.; Choi, M.; Sridharan, G.V.; Sherr, D.H.; Yarmush, M.L.; Alaniz, R.C.;
Jayaraman, A.; Lee, K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response
in Hepatocytes and Macrophages. Cell Rep. 2018, 23, 1099–1111. [CrossRef]
64. Russell, W.R.; Duncan, S.H.; Scobbie, L.; Duncan, G.; Cantlay, L.; Calder, A.G.; Anderson, S.E.; Flint, H.J.
Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of
protein. Mol. Nutr. Food Res. 2013, 57, 523–535. [CrossRef]
65. Hoyles, L.; Fernandez-Real, J.M.; Federici, M.; Serino, M.; Abbott, J.; Charpentier, J.; Heymes, C.; Luque, J.L.;
Anthony, E.; Barton, R.H.; et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic
obese women. Nat. Med. 2018, 24, 1070–1080. [CrossRef] [PubMed]
66. Pedersen, H.K.; Gudmundsdottir, V.; Nielsen, H.B.; Hyotylainen, T.; Nielsen, T.; Jensen, B.A.; Forslund, K.;
Hildebrand, F.; Prifti, E.; Falony, G.; et al. Human gut microbes impact host serum metabolome and insulin
sensitivity. Nature 2016, 535, 376–381. [CrossRef] [PubMed]
67. Shoaie, S.; Ghaffari, P.; Kovatcheva-Datchary, P.; Mardinoglu, A.; Sen, P.; Pujos-Guillot, E.; de Wouters, T.;
Juste, C.; Rizkalla, S.; Chilloux, J.; et al. Quantifying Diet-Induced Metabolic Changes of the Human Gut
Microbiome. Cell Metab. 2015, 22, 320–331. [CrossRef] [PubMed]
68. Chen, Y.M.; Liu, Y.; Zhou, R.F.; Chen, X.L.; Wang, C.; Tan, X.Y.; Wang, L.J.; Zheng, R.D.; Zhang, H.W.;
Ling, W.H.; et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and
choline with non-alcoholic fatty liver disease in adults. Sci. Rep. 2016, 6, 19076. [CrossRef]
69. Duseja, A.; Acharya, S.K.; Mehta, M.; Chhabra, S.; Shalimar; Rana, S.; Das, A.; Dattagupta, S.; Dhiman, R.K.;
Chawla, Y.K. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease
(NAFLD): A randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019, 6, e000315.
[CrossRef]
70. Buchman, A.L.; Dubin, M.D.; Moukarzel, A.A.; Jenden, D.J.; Roch, M.; Rice, K.M.; Gornbein, J.; Ament, M.E.
Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with
intravenous choline supplementation. Hepatology 1995, 22, 1399–1403.
71. Gao, X.; Liu, X.; Xu, J.; Xue, C.; Xue, Y.; Wang, Y. Dietary trimethylamine N-oxide exacerbates impaired
glucose tolerance in mice fed a high fat diet. J. Biosci. Bioeng. 2014, 118, 476–481. [CrossRef] [PubMed]
72. Dumas, M.E.; Barton, R.H.; Toye, A.; Cloarec, O.; Blancher, C.; Rothwell, A.; Fearnside, J.; Tatoud, R.; Blanc, V.;
Lindon, J.C.; et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in
insulin-resistant mice. Proc. Nat. Acad. Sci. USA 2006, 103, 12511–12516. [CrossRef] [PubMed]
73. Nair, S.; Cope, K.; Risby, T.H.; Diehl, A.M. Obesity and female gender increase breath ethanol concentration:
Potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001,
96, 1200–1204. [CrossRef]
74. Volynets, V.; Kuper, M.A.; Strahl, S.; Maier, I.B.; Spruss, A.; Wagnerberger, S.; Konigsrainer, A.; Bischoff, S.C.;
Bergheim, I. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with
nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 2012, 57, 1932–1941. [CrossRef] [PubMed]
Nutrients 2019, 11, 2837 20 of 22
75. Begriche, K.; Igoudjil, A.; Pessayre, D.; Fromenty, B. Mitochondrial dysfunction in NASH: Causes,
consequences and possible means to prevent it. Mitochondrion 2006, 6, 1–28. [CrossRef]
76. Elamin, E.; Masclee, A.; Troost, F.; Dekker, J.; Jonkers, D. Cytotoxicity and metabolic stress induced by
acetaldehyde in human intestinal LS174T goblet-like cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2014,
307, G286–G294. [CrossRef]
77. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.;
Roe, B.A.; Affourtit, J.P.; et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480–484.
[CrossRef]
78. Broeders, E.P.; Nascimento, E.B.; Havekes, B.; Brans, B.; Roumans, K.H.; Tailleux, A.; Schaart, G.; Kouach, M.;
Charton, J.; Deprez, B.; et al. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue
Activity. Cell Metab. 2015, 22, 418–426. [CrossRef]
79. Boets, E.; Deroover, L.; Houben, E.; Vermeulen, K.; Gomand, S.V.; Delcour, J.A.; Verbeke, K. Quantification of
in Vivo Colonic Short Chain Fatty Acid Production from Inulin. Nutrients 2015, 7, 8916–8929. [CrossRef]
80. Canfora, E.E.; van der Beek, C.M.; Jocken, J.W.E.; Goossens, G.H.; Holst, J.J.; Olde Damink, S.W.M.;
Lenaerts, K.; Dejong, C.H.C.; Blaak, E.E. Colonic infusions of short-chain fatty acid mixtures promote energy
metabolism in overweight/obese men: A randomized crossover trial. Sci. Rep. 2017, 7, 2360. [CrossRef]
81. Degnan, F.H. The US Food and Drug Administration and probiotics: Regulatory categorization. Clin. Infect.
Dis. 2008, 46 (Suppl. 2), S133–S136; discussion S144–S151. [CrossRef]
82. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.;
Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The International Scientific Association for
Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev.
Gastroenterol. Hepatol. 2017, 14, 491–502. [CrossRef]
83. Olveira, G.; Gonzalez-Molero, I. An update on probiotics, prebiotics and synbiotics in clinical nutrition.
Endocrinol. Nutr. 2016, 63, 482–494. [CrossRef] [PubMed]
84. Liang, Y.; Liang, S.; Zhang, Y.; Deng, Y.; He, Y.; Chen, Y.; Liu, C.; Lin, C.; Yang, Q. Oral Administration of
Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation
via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. Probiotics Antimicrob. Proteins
2019, 11, 175–185. [CrossRef] [PubMed]
85. Cortez-Pinto, H.; Borralho, P.; Machado, J.; Lopes, M.T.; Gato, I.V.; Santos, A.M.; Guerreiro, A.S. Microbiota
Modulation with Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of
Non-Alcoholic Steatohepatitis (NASH). GE Port. J. Gastroenterol. 2016, 23, 132–141. [CrossRef] [PubMed]
86. Xin, J.; Zeng, D.; Wang, H.; Ni, X.; Yi, D.; Pan, K.; Jing, B. Preventing non-alcoholic fatty liver disease through
Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut
environment in obese mice. Appl. Microbiol. Biotechnol. 2014, 98, 6817–6829. [CrossRef] [PubMed]
87. Velayudham, A.; Dolganiuc, A.; Ellis, M.; Petrasek, J.; Kodys, K.; Mandrekar, P.; Szabo, G. VSL#3 probiotic
treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis
model in mice. Hepatology 2009, 49, 989–997. [CrossRef] [PubMed]
88. Li, Z.; Yang, S.; Lin, H.; Huang, J.; Watkins, P.A.; Moser, A.B.; Desimone, C.; Song, X.Y.; Diehl, A.M. Probiotics
and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology
2003, 37, 343–350. [CrossRef]
89. Aller, R.; De Luis, D.A.; Izaola, O.; Conde, R.; Gonzalez Sagrado, M.; Primo, D.; De La Fuente, B.; Gonzalez, J.
Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind
randomized clinical trial. Eur. Rev. Med. Pharm. Sci. 2011, 15, 1090–1095.
90. Vajro, P.; Mandato, C.; Licenziati, M.R.; Franzese, A.; Vitale, D.F.; Lenta, S.; Caropreso, M.; Vallone, G.;
Meli, R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr.
Gastroenterol. Nutr. 2011, 52, 740–743. [CrossRef]
91. Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.;
Malaguarnera, G.; Mistretta, A.; Li Volti, G.; et al. Bifidobacterium longum with fructo-oligosaccharides in
patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57, 545–553. [CrossRef] [PubMed]
92. Shavakhi, A.; Minakari, M.; Firouzian, H.; Assali, R.; Hekmatdoost, A.; Ferns, G. Effect of a Probiotic and
Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized
Clinical Trial. Int. J. Prev. Med. 2013, 4, 531–537. [PubMed]
Nutrients 2019, 11, 2837 21 of 22
93. Wong, V.W.; Won, G.L.; Chim, A.M.; Chu, W.C.; Yeung, D.K.; Li, K.C.; Chan, H.L. Treatment of nonalcoholic
steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 2013, 12, 256–262. [CrossRef]
94. Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.;
Nobili, V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic
steatohepatitis. Aliment. Pharm. 2014, 39, 1276–1285. [CrossRef]
95. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic
supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot
study. Am. J. Clin. Nutr. 2014, 99, 535–542. [CrossRef]
96. Nabavi, S.; Rafraf, M.; Somi, M.H.; Homayouni-Rad, A.; Asghari-Jafarabadi, M. Effects of probiotic yogurt
consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J. Dairy Sci. 2014,
97, 7386–7393. [CrossRef]
97. Miccheli, A.; Capuani, G.; Marini, F.; Tomassini, A.; Pratico, G.; Ceccarelli, S.; Gnani, D.; Baviera, G.; Alisi, A.;
Putignani, L.; et al. Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing
VSL#3 treatment. Int. J. Obes (Lond) 2015, 39, 1118–1125. [CrossRef]
98. Asgharian, A.; Askari, G.; Esmailzade, A.; Feizi, A.; Mohammadi, V. The Effect of Symbiotic Supplementation
on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver
Disease: A Clinical Trial. Int. J. Prev. Med. 2016, 7, 59. [CrossRef]
99. Ferolla, S.M.; Couto, C.A.; Costa-Silva, L.; Armiliato, G.N.; Pereira, C.A.; Martins, F.S.; Ferrari Mde, L.;
Vilela, E.G.; Torres, H.O.; Cunha, A.S.; et al. Beneficial Effect of Synbiotic Supplementation on Hepatic
Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic
Steatohepatitis. Nutrients 2016, 8, 397. [CrossRef]
100. Sepideh, A.; Karim, P.; Hossein, A.; Leila, R.; Hamdollah, M.; Mohammad, E.G.; Mojtaba, S.; Mohammad, S.;
Ghader, G.; Seyed Moayed, A. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory
Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J. Am.
Coll Nutr. 2016, 35, 500–505. [CrossRef]
101. Abdel Monem, S.M. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University
Hospitals. Euroasian J. Hepatogastroenterol. 2017, 7, 101–106. [CrossRef] [PubMed]
102. Behrouz, V.; Jazayeri, S.; Aryaeian, N.; Zahedi, M.J.; Hosseini, F. Effects of Probiotic and Prebiotic
Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A
Randomized Clinical Trial. Middle East. J. Dig. Dis. 2017, 9, 150–157. [CrossRef]
103. Ekhlasi, G.; Zarrati, M.; Agah, S.; Hosseini, A.F.; Hosseini, S.; Shidfar, S.; Soltani Aarbshahi, S.S.; Razmpoosh, E.;
Shidfar, F. Effects of synbiotics and vitamin E supplementation on blood pressure, nitric oxide and
inflammatory factors in non-alcoholic fatty liver disease. EXCLI J. 2017, 16, 278–290. [CrossRef]
104. Famouri, F.; Shariat, Z.; Hashemipour, M.; Keikha, M.; Kelishadi, R. Effects of Probiotics on Nonalcoholic
Fatty Liver Disease in Obese Children and Adolescents. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 413–417.
[CrossRef]
105. Manzhalii, E.; Virchenko, O.; Falalyeyeva, T.; Beregova, T.; Stremmel, W. Treatment efficacy of a probiotic
preparation for non-alcoholic steatohepatitis: A pilot trial. J. Dig. Dis. 2017, 18, 698–703. [CrossRef]
106. Mofidi, F.; Poustchi, H.; Yari, Z.; Nourinayyer, B.; Merat, S.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A.
Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised,
double-blind, placebo-controlled, clinical trial. Br. J. Nutr. 2017, 117, 662–668. [CrossRef]
107. Bakhshimoghaddam, F.; Shateri, K.; Sina, M.; Hashemian, M.; Alizadeh, M. Daily Consumption of Synbiotic
Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled
Clinical Trial. J. Nutr. 2018, 148, 1276–1284. [CrossRef]
108. Javadi, L.; Khoshbaten, M.; Safaiyan, A.; Ghavami, M.; Abbasi, M.M.; Gargari, B.P. Pro- and prebiotic effects
on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease. Asia Pac. J. Clin. Nutr.
2018, 27, 1031–1039. [CrossRef]
109. Kobyliak, N.; Abenavoli, L.; Falalyeyeva, T.; Mykhalchyshyn, G.; Boccuto, L.; Kononenko, L.; Kyriienko, D.;
Komisarenko, I.; Dynnyk, O. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD:
A randomized clinical study. Minerva Med. 2018, 109, 418–428. [CrossRef]
110. Kobyliak, N.; Abenavoli, L.; Mykhalchyshyn, G.; Kononenko, L.; Boccuto, L.; Kyriienko, D.; Dynnyk, O. A
Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD
Patients: Evidence from a Randomized Clinical Trial. J. Gastrointestin. Liver Dis. 2018, 27, 41–49. [CrossRef]
Nutrients 2019, 11, 2837 22 of 22
111. Sayari, S.; Neishaboori, H.; Jameshorani, M. Combined effects of synbiotic and sitagliptin versus sitagliptin
alone in patients with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2018, 24, 331–338. [CrossRef]
[PubMed]
112. Wang, W.; Shi, L.P.; Shi, L.; Xu, L. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease.
Zhonghua Nei Ke Za Zhi 2018, 57, 101–106. [CrossRef] [PubMed]
113. Ahn, S.B.; Jun, D.W.; Kang, B.K.; Lim, J.H.; Lim, S.; Chung, M.J. Randomized, Double-blind, Placebo-controlled
Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci. Rep. 2019, 9, 5688.
[CrossRef]
114. Loman, B.R.; Hernandez-Saavedra, D.; An, R.; Rector, R.S. Prebiotic and probiotic treatment of nonalcoholic
fatty liver disease: A systematic review and meta-analysis. Nutr. Rev. 2018, 76, 822–839. [CrossRef]
115. Khan, M.Y.; Mihali, A.B.; Rawala, M.S.; Aslam, A.; Siddiqui, W.J. The promising role of probiotic and
synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty
liver disease—A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2019, 31, 703–715.
[CrossRef]
116. Koutnikova, H.; Genser, B.; Monteiro-Sepulveda, M.; Faurie, J.M.; Rizkalla, S.; Schrezenmeir, J.; Clement, K.
Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: A
systematic review and meta-analysis of randomised controlled trials. BMJ Open 2019, 9, e017995. [CrossRef]
117. Liu, L.; Li, P.; Liu, Y.; Zhang, Y. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty
Liver Disease: A Meta-Analysis. Dig. Dis. Sci. 2019. [CrossRef]
118. Sharpton, S.R.; Maraj, B.; Harding-Theobald, E.; Vittinghoff, E.; Terrault, N.A. Gut microbiome-targeted
therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Am. J.
Clin. Nutr. 2019. [CrossRef]
119. Sigrist, R.M.S.; Liau, J.; Kaffas, A.E.; Chammas, M.C.; Willmann, J.K. Ultrasound Elastography: Review of
Techniques and Clinical Applications. Theranostics 2017, 7, 1303–1329. [CrossRef]
120. Idilman, I.S.; Aniktar, H.; Idilman, R.; Kabacam, G.; Savas, B.; Elhan, A.; Celik, A.; Bahar, K.; Karcaaltincaba, M.
Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology
2013, 267, 767–775. [CrossRef]
121. Hempel, S.; Newberry, S.; Ruelaz, A.; Wang, Z.; Miles, J.N.; Suttorp, M.J.; Johnsen, B.; Shanman, R.; Slusser, W.;
Fu, N.; et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid. Rep. Technol. Assess.
(Full Rep.) 2011, 200, 1–645.
122. Doron, S.; Snydman, D.R. Risk and safety of probiotics. Clin. Infect. Dis. 2015, 60 (Suppl. 2), S129–S134.
[CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
